JACOB GARY S 4

4 · Cardiff Oncology, Inc. · Filed Jun 15, 2021

Form 4

Period: 2021-06-10

Director

Transactions

Other
Stock Options
2021-06-10+223→ 76,106 total
Exercise: $372.96From: 2017-01-04Exp: 2023-06-10→ Common Stock (223 underlying)
Other
Stock Options
2021-06-10+755→ 76,106 total
Exercise: $21.60From: 2019-01-23Exp: 2023-06-10→ Common Stock (755 underlying)
Other
Stock Options
2021-06-10+44,734→ 76,106 total
Exercise: $2.48From: 2020-06-20Exp: 2023-06-10→ Common Stock (44,734 underlying)
Other
Stock Options
2021-06-10+28,858→ 76,106 total
Exercise: $2.60From: 2021-06-10Exp: 2023-06-10→ Common Stock (28,858 underlying)
Other
Stock Options
2021-06-10+293→ 76,106 total
Exercise: $447.84Exp: 2023-06-10→ Common Stock (293 underlying)
Other
Stock Options
2021-06-10+218→ 76,106 total
Exercise: $316.08From: 2014-12-11Exp: 2023-06-10→ Common Stock (218 underlying)
Other
Stock Options
2021-06-10+223→ 76,106 total
Exercise: $516.96From: 2016-03-17Exp: 2023-06-10→ Common Stock (223 underlying)
Other
Stock Options
2021-06-10+530→ 76,106 total
Exercise: $51.84From: 2018-10-04Exp: 2023-06-10→ Common Stock (530 underlying)

Footnotes (3)

[F1]In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 28,858 stock options to June 10, 2021 from June 17, 2021. In addition, the Compensation Committee extended the expiration date of the stock options to June 10, 2023.
[F2]Expiration date of the stock options was extended to June 10, 2023.
[F3]8,805 of the stock options vest immediately. 4,077 of the stock options vest on each of 2/25/2015 and 2016 and 4,076 of the stock options vest on 2/25/2017.

Documents

1 file